Alphamab Oncology Presents Promising JSKN003 Research at ASCO 2025

Alphamab Oncology ( (HK:9966) ) has issued an update.

Alphamab Oncology has announced research updates for its drug JSKN003, presented at the 2025 ASCO Annual Meeting. The updates highlight the drug’s efficacy and safety in treating advanced solid tumors, including platinum-resistant ovarian cancer and heavily pretreated HER2-positive breast cancer. The studies show promising results, with significant tumor shrinkage and manageable safety profiles, positioning JSKN003 as a potential treatment option in ongoing phase III trials.

The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company focused on the development of innovative cancer therapies. The company primarily engages in the research and development of monoclonal antibodies and other biologics aimed at treating various types of cancer, with a market focus on oncology treatments.

Average Trading Volume: 4,443,260

Technical Sentiment Signal: Hold

Current Market Cap: HK$8.62B

For an in-depth examination of 9966 stock, go to TipRanks’ Stock Analysis page.